Titan’s Probuphine gains more media attention
Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids.
Independent TV station, WHDT, in Stuart, FL. has produced a segment on Probuphine with Dr. Stuart Segal and one of his patients, who was successfully weaned off her use of opioids.
Dr. Segal is medical director of the Segal Institute for Clinical Research in Florida and was a lead investigator for the pivotal trial that resulted in FDA approval of Probuphine earlier this year. Braeburn Pharmaceuticals is Titan’s sales and marketing partner for the implant.